Holen Sie sich die Stockscreener-App
81.39
2.08%
1.66
Vorhandelsmarkt:
81.39
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$79.73
Offen:
$79.55
24-Stunden-Volumen:
5.34M
Relative Volume:
1.05
Marktkapitalisierung:
$46.86B
Einnahmen:
$6.30B
Nettoeinkommen (Verlust:
$1.07B
KGV:
44.22
EPS:
1.8406
Netto-Cashflow:
$1.09B
1W Leistung:
-2.18%
1M Leistung:
+4.19%
6M Leistung:
-5.48%
1J Leistung:
+7.80%
1-Tages-Spanne:
$78.29
$81.73
1-Wochen-Bereich:
$76.49
$84.42
52-Wochen-Spanne:
$72.30
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
81.39 | 45.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
83.83 | 146.92B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
302.09 | 112.88B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.21 | 98.63B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.06 | 80.41B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-01 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Are Wall Street Analysts Bullish on Edwards Lifesciences Stock? - Barchart.com
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
VIRGINIA RETIREMENT SYSTEMS ET Al Trims Stake in Edwards Lifesciences Corporation $EW - MarketBeat
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
Edwards Lifesciences CEO Zovighian sells $2.83m in shares By Investing.com - Investing.com Nigeria
Edwards Lifesciences CEO Zovighian sells $2.83m in shares - Investing.com
Edwards Lifesciences (EW) executive vests performance units and withholds shares for taxes - Stock Titan
Edwards Lifesciences (NYSE: EW) lists vested RSUs and prior 22,430-share sale - Stock Titan
Edwards Lifesciences CVP Wayne Markowitz sells $47,279 in stock By Investing.com - Investing.com Nigeria
Edwards Lifesciences CVP Wayne Markowitz sells $47,279 in stock - Investing.com UK
Edwards Lifesciences (NYSE: EW) CFO exercises performance units, withholds 11,004 shares for taxes - Stock Titan
Edwards Lifesciences (EW) CEO awarded stock, options and makes share gifts - Stock Titan
Edwards Lifesciences (NYSE: EW) executive logs routine tax-withholding share disposition - Stock Titan
Is Edwards Lifesciences Corp (EW) a Bargain After 3.5% Drop? GF Value Says Undervalued - GuruFocus
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
[144] Edwards Lifesciences Corp SEC Filing - Stock Titan
Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise - Yahoo! Finance Canada
Nwam LLC Grows Position in Edwards Lifesciences Corporation $EW - MarketBeat
EW SEC FilingsEdwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Generali Asset Management SPA SGR Has $6.18 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE: EW) awards RSUs and options to CVP Daveen Chopra - Stock Titan
Edwards Lifesciences Corp (EW) Shares Fall 3.4% -- What GF Score of 97 Tells Investors - GuruFocus
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE: EW) investors approve equity and pay measures - Stock Titan
Swedbank AB Sells 192,442 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Principal Financial Group Inc. Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
QRG Capital Management Inc. Acquires 18,172 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE: EW) lifts Q1 2026 sales on TAVR and TMTT growth - Stock Titan
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences Appoints Theodora Mistras as Chief Financial Officer Effective May 2026 - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock - Investing.com UK
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) CVP Lippis sells 2,038 shares after option exercises - Stock Titan
Edwards Lifesciences (EW) executive logs 282-share tax withholding on Form 4 - Stock Titan
Edwards Lifesciences (EW) VP Donald Bobo logs tax share disposal and holdings - Stock Titan
Edwards Lifesciences names Doretta Mistras as new CFO - Investing.com
Theodora Mistras to Become Edwards Lifesciences CFO, Succeeding Scott Ullem - TradingView
New Edwards Lifesciences (NYSE: EW) CFO to receive $925K salary and major equity - Stock Titan
Edwards Lifesciences Announces Appointment of CFO - Yahoo Finance
Edwards Lifesciences (NYSE: EW) files Form 144; insider disposals listed - Stock Titan
Possible Bearish Signals With Edwards Lifesciences Insiders Disposing Stock - Yahoo Finance
Edwards Lifesciences Corporation (EW) Stock Analysis: 15.68% Potential Upside Beckons Investors - DirectorsTalk Interviews
TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE - Yahoo Finance
PFA Pension Forsikringsaktieselskab Buys Shares of 543,261 Edwards Lifesciences Corporation $EW - MarketBeat
M&T Bank Corp Cuts Position in Edwards Lifesciences Corporation $EW - MarketBeat
After 10 years, Edwards valve tissue shows 97.9% freedom from deterioration - Stock Titan
Edwards Lifesciences Corporation $EW Stake Lessened by Kornitzer Capital Management Inc. KS - MarketBeat
Edwards Lifesciences Corporation $EW Shares Sold by Caisse Des Depots ET Consignations - MarketBeat
Exencial Wealth Advisors LLC Trims Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):